Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Prednisolone acetate
Drug ID BADD_D01832
Description Prednisolone acetate is a [prednisolone] molecule bound to an acetate functional group by an ester bond.[L9449] Prednisolone acetate was granted FDA approval in 1955.[L9449]
Indications and Usage Prednisolone acetate is indicated as an anti-inflammatory or immunosuppressive agent for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, or infectious conditions.[L9449] Prednisolone acetate is also indicated in organ transplant patients, as well as endocrine or neoplastic conditions.[L9449]
Marketing Status approved; vet_approved
ATC Code Not Available
DrugBank ID DB15566
KEGG ID D00980
MeSH ID C009935
PubChem ID 5834
TTD Drug ID Not Available
NDC Product Code 38779-0152; 62991-1692; 50090-0559; 50090-1912; 50090-5275; 61314-637; 49452-5990; 82298-107; 11980-180; 60758-119; 60722-3006; 82298-108; 52128-150; 11980-174; 46439-8761; 51552-0027; 64958-0048; 76420-204; 22552-0044; 68071-2222
UNII 8B2807733D
Synonyms prednisolone acetate | prednisolone 21-acetate | pred forte | Scherisolone-Kristall suspension
Chemical Information
Molecular Formula C23H30O6
CAS Registry Number 52-21-1
SMILES CC(=O)OCC(=O)C1(CCC2C1(CC(C3C2CCC4=CC(=O)C=CC34C)O)C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Paraparesis17.01.04.006--Not Available
Paraplegia17.01.04.007--Not Available
Pathological fracture12.04.02.006; 16.32.03.007; 15.08.02.008--Not Available
Peptic ulcer07.04.07.001--Not Available
Personality change19.05.01.006; 17.02.05.019--
Petechiae24.07.06.004; 23.06.01.003; 01.01.03.002--Not Available
Photophobia17.17.02.006; 06.01.01.0040.013169%
Pruritus23.03.12.001--
Pulmonary oedema22.01.03.003; 02.05.02.003--
Rash23.03.13.001--Not Available
Secondary adrenocortical insufficiency05.03.04.012; 14.11.01.014--Not Available
Seizure17.12.03.001--
Sensory disturbance17.02.07.006--Not Available
Shock24.06.02.002--Not Available
Skin atrophy23.01.05.001--
Skin hyperpigmentation23.05.01.003--
Skin hypopigmentation23.05.02.003--
Skin striae23.01.05.002--Not Available
Sodium retention14.05.04.003--Not Available
Spermatozoa abnormal13.20.04.009--Not Available
Spermatozoa progressive motility abnormal13.20.04.011--Not Available
Spinal compression fracture15.08.05.004; 14.04.04.003; 12.04.04.001--Not Available
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Tachycardia02.03.02.007--Not Available
Tendon rupture15.07.01.008; 12.01.07.003--Not Available
Thrombophlebitis24.01.02.001--Not Available
Transplant rejection12.02.05.022; 10.02.03.0020.014032%Not Available
Urticaria23.04.02.001; 10.01.06.001--
Uveitis10.02.01.023; 06.04.03.0030.013169%
Vasculitis24.12.04.027; 10.02.02.006--
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages